

PlasmaGen Biosciences raises Rs 150 Cr marking strong growth trajectory

22 December 2025 | News

Company scales operations and pursues international expansion



PlasmaGen Biosciences, a leading biopharmaceutical company focused on blood plasma-derived therapeutics, has raised Rs 150 crore in a minority equity financing round at an Rs 1500+ crore valuation. The round was led by ViNS Bioproducts, a specialty biopharma company, with participation from prominent HNI family offices, pharmaceutical entrepreneurs and existing investors.

The financing reflects strong investor conviction in PlasmaGen's operating model, manufacturing infrastructure, and long-term potential as a differentiated plasma biopharmaceutical platform. Since commencing commercial operations at its state-of-the-art manufacturing facility in 2024 - India's first such facility by a pure-play company and only the fifth plasma fractionation facility in the country - PlasmaGen has delivered rapid revenue growth and is now preparing to enter international markets.

Founded in 2010 and headquartered in Bengaluru, PlasmaGen has raised over Rs 600 crore in total funding to date. The fresh capital will be deployed towards scaling international operations, expanding the product portfolio and strengthening organizational capabilities.

The company has identified distribution partners in key export markets and is advancing regulatory approvals to commence international operations. Domestically, PlasmaGen continues to strengthen its market presence with its portfolio of plasma-derived therapeutics addressing significant unmet medical needs.